Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Feb 27, 2017
Valuentum's Brian Nelson to Present at CFA Society of Houston
Valuentum's Brian Nelson has been invited to speak at the CFA Society of Houston in March of this year! Mr. Nelson will walk through his experiences in valuation and financial statement analysis within the stock selection process to help portfolio managers learn how to optimize the strength and resilience of client portfolios--those either built for capital appreciation or income, or both. Feb 27, 2017
Recent Material Fair Value Estimate Changes
Fair value estimates are never static. Let's walk through some of the more material ones we've made during the past month or so. Feb 27, 2017
Dividend Increases/Decreases for the Week Ending February 24
Let's take a look at companies raising/lowering their dividends this week. Feb 24, 2017
Average Check Increases Driving Results for Cracker Barrel
Image Source: Mike Mozart. Dividend Growth Newsletter portfolio holding Cracker Barrel drove average check increases to combat weak traffic that continues to plague the restaurant space. Feb 23, 2017
Is Clean Energy Just Burning Cash?
Image Source: Chuck Coker. Clean or renewable energy sources will undoubtedly be a part of how we generate power in the future, but how investible is the space? The answer is largely dependent on your risk tolerance. Feb 23, 2017
PBMs: Express Scripts and CVS’ Looming Victory?
Image Source: Victor. We’re expecting a big win at CVS in coming years, and it may come at the expense of Express Scripts. Feb 23, 2017
3 Critical Drug Approvals For Your Radar
Image Source: Neurocrine Biosciences. What can investors expect when it comes to imminent drug approvals? Let’s cover three important ones. Feb 20, 2017
Dividend Increases/Decreases for the Week Ending February 17
Let's take a look at companies raising/lowering their dividends this week. Feb 18, 2017
Johnson & Johnson's Oncology Division A Force to Be Reckoned With
Image Source: Open Grid Scheduler. Healthcare and consumer staples giant Johnson & Johnson is a core holding in both newsletter portfolios. Let’s take a deep dive into one of its key sources of growth, its ‘Pharmaceutical’ segment. Feb 17, 2017
Cisco Accelerating Recurring Revenue Base, Raises Dividend Double Digits
Image Source: Brandon Leon. Newsletter portfolio holding Cisco continues to transition its business to a software and subscription-based model. Let’s take a look its progress as of its second quarter of fiscal 2017.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|